Bronchogen
Бронхоген
Target Organ
Bronchi
Description
Bronchogen is a synthetic peptide bioregulator specifically designed to support bronchial health and respiratory function. As a Generation 2 Cytogen, it contains a short-chain peptide sequence that targets the bronchial mucosa, the tissue lining the airways that carries air to and from the lungs. Bronchogen has been extensively studied for its ability to restore the structural integrity of bronchial tissue, reduce chronic inflammation in the airways, and improve overall respiratory function. Clinical trials have demonstrated significant improvements in lung function parameters (FEV1, FVC), reduction in exacerbations, and enhanced quality of life in patients with chronic obstructive pulmonary disease (COPD), chronic bronchitis, and asthma. The peptide works at the cellular level to normalize metabolic processes in bronchial cells, enhance mucociliary clearance (the lungs natural cleaning mechanism), and reduce the inflammatory cascade that damages airways over time. Bronchogen is particularly valuable for individuals with chronic respiratory conditions, smokers recovering from lung damage, and those exposed to environmental pollutants or occupational respiratory hazards.
⚙️ Mechanism of Action
Bronchogen functions by regulating gene expression and protein synthesis in bronchial epithelial cells and smooth muscle tissue. It modulates the activity of key inflammatory mediators (CRP, IL-6, TNF-alpha), reducing the chronic inflammation that characterizes respiratory diseases. The peptide enhances the repair of damaged bronchial mucosa, promotes regeneration of ciliated epithelial cells essential for mucus clearance, and strengthens the barrier function of the respiratory epithelium. By improving microcirculation in bronchial tissue and reducing edema (swelling), Bronchogen helps restore normal airway diameter and reduces airway hyperreactivity. It also supports the production of surfactant proteins that keep airways open and facilitate gas exchange. The mechanisms result in measurable improvements in spirometry parameters: increased FEV1 (forced expiratory volume in 1 second), improved FVC (forced vital capacity), and enhanced exercise tolerance as measured by the 6-minute walk test.
✓ Primary Benefits
- ·Significantly improves lung function (FEV1 increased by 148mL in clinical trials)
- ·Reduces COPD exacerbations by 58% over 6 months
- ·Decreases chronic coughing and improves airway clearance
- ·Reduces systemic inflammation (CRP, IL-6 markers)
- ·Improves exercise capacity and daily functional ability
- ·Enhances quality of life and reduces respiratory symptoms
- ·Supports bronchial tissue repair and regeneration
- ·Reduces airway hyperreactivity in asthma patients
💊Dosing Protocol
Standard Course
1-2 capsules daily for 10-30 days
Intensive Course
Clinical studies used 20mg twice daily for 60 days for COPD; repeat courses every 3-6 months for chronic conditions